HUTCHMED (China) Ltd
HCM13.550USD
+0.200+1.50%
收盤 12/19, 16:00（美東）報價延遲15分鐘
11.82B總市值
25.06本益比TTM
關於 HUTCHMED (China) Ltd 公司
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
HUTCHMED (China) Ltd簡介
公司代碼HCM
公司名稱HUTCHMED (China) Ltd
上市日期May 19, 2006
CEOCheng (Chig Fung)
員工數量1811
證券類型Depository Receipt
年結日May 19
公司地址48th Floor, Cheung Kong Center, 2 Queen's Road Central
城市
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Hong Kong
郵編- -
電話85221281188
網址https://www.hutch-med.com/
公司代碼HCM
上市日期May 19, 2006
CEOCheng (Chig Fung)
HUTCHMED (China) Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2024
FY2023
FY2022
FY2021
FY2020
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
其他
97.71%
持股股東
持股股東
佔比
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
其他
97.71%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
2.31%
Investment Advisor
0.76%
Research Firm
0.22%
Hedge Fund
0.13%
Individual Investor
0.12%
Bank and Trust
0.03%
Sovereign Wealth Fund
0.01%
其他
96.41%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
144
6.22M
3.56%
-5.80M
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
2023Q2
352
26.00M
15.01%
-20.74M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Schroder Investment Management (Singapore) Ltd.
1.77M
1.02%
-97.80K
-5.23%
Jun 30, 2025
Allianz Global Investors Asia Pacific Limited
878.74K
0.5%
-67.00K
-7.08%
Jun 30, 2025
Schroder Investment Management (Hong Kong) Ltd.
805.63K
0.46%
-166.36K
-17.12%
Jun 30, 2025
Jane Street Capital, L.L.C.
175.96K
0.1%
-46.28K
-20.82%
Jun 30, 2025
State Street Investment Management (US)
328.79K
0.19%
-8.07K
-2.40%
Jun 30, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Jun 30, 2025
Amundi Asset Management, SAS
157.43K
0.09%
--
--
Jun 30, 2025
M&G Investment Management Ltd.
259.62K
0.15%
+924.00
+0.36%
Jun 30, 2025
Su (Weiguo Ph.D.)
183.98K
0.11%
+183.98K
--
Mar 04, 2024
Renaissance Technologies LLC
129.00K
0.07%
-6.20K
-4.59%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Tema Oncology ETF
0.78%
National Security Emerging Markets Index ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Tema Oncology ETF
佔比0.78%
National Security Emerging Markets Index ETF
佔比0.35%
Invesco Nasdaq Biotechnology ETF
佔比0.05%
ProShares Ultra Nasdaq Biotechnology
佔比0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
佔比0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
佔比0%
ActivePassive International Equity ETF
佔比0%
SPDR Portfolio Developed World ex-US ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
HUTCHMED (China) Ltd的前五大股東是誰？
HUTCHMED (China) Ltd的前五大股東如下：
Schroder Investment Management (Singapore) Ltd.持有股份：1.77M佔總股份比例：1.02%。
Allianz Global Investors Asia Pacific Limited持有股份：878.74K佔總股份比例：0.50%。
Schroder Investment Management (Hong Kong) Ltd.持有股份：805.63K佔總股份比例：0.46%。
Jane Street Capital, L.L.C.持有股份：175.96K佔總股份比例：0.10%。
State Street Investment Management (US)持有股份：328.79K佔總股份比例：0.19%。
Schroder Investment Management (Singapore) Ltd.持有股份：1.77M佔總股份比例：1.02%。
Allianz Global Investors Asia Pacific Limited持有股份：878.74K佔總股份比例：0.50%。
Schroder Investment Management (Hong Kong) Ltd.持有股份：805.63K佔總股份比例：0.46%。
Jane Street Capital, L.L.C.持有股份：175.96K佔總股份比例：0.10%。
State Street Investment Management (US)持有股份：328.79K佔總股份比例：0.19%。
HUTCHMED (China) Ltd的前三大股東類型是什麼？
HUTCHMED (China) Ltd 的前三大股東類型分別是：
Schroder Investment Management (Singapore) Ltd.
Allianz Global Investors Asia Pacific Limited
Schroder Investment Management (Hong Kong) Ltd.
Schroder Investment Management (Singapore) Ltd.
Allianz Global Investors Asia Pacific Limited
Schroder Investment Management (Hong Kong) Ltd.
有多少機構持有HUTCHMED (China) Ltd(HCM)的股份？
截至2025Q3，共有144家機構持有HUTCHMED (China) Ltd的股份，合計持有的股份價值約為6.22M，占公司總股份的3.56% 。與2025Q2相比，機構持股有所增加，增幅為-0.43%。
哪個業務部門對HUTCHMED (China) Ltd的收入貢獻最大？
在FY2024，--業務部門對HUTCHMED (China) Ltd的收入貢獻最大，創收--，占總收入的--% 。
